366 related articles for article (PubMed ID: 32299814)
1. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
[TBL] [Abstract][Full Text] [Related]
2. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
[TBL] [Abstract][Full Text] [Related]
3. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
[TBL] [Abstract][Full Text] [Related]
4. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.
Yap TA; LoRusso PM; Wong DJ; Hu-Lieskovan S; Papadopoulos KP; Holz JB; Grabowska U; Gradinaru C; Leung KM; Marshall S; Reader CS; Russell R; Sainson RCA; Seal CJ; Shepherd CJ; Germaschewski F; Gliddon D; Stern O; Young L; Brewis N; Kayitalire L; Morrow M
Clin Cancer Res; 2023 Mar; 29(5):888-898. PubMed ID: 36342102
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
8. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
[TBL] [Abstract][Full Text] [Related]
9. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
10. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
[TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
[TBL] [Abstract][Full Text] [Related]
14. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
15. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
16. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
[TBL] [Abstract][Full Text] [Related]
17. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
19. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
20. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]